Document is current
Any future updates will be listed below
-
Authors
Pang, Wei
Lu, Ying
Zhao, Yan-Bo
Shen, Fan
Fan, Chang-Fa
Wang, Qian
He, Wen-Qiang
He, Xiao-Yan
Li, Ze-Kai
Chen, Tao-Tao
Yang, Cui-Xian
Li, You-Zhi
Xiao, Si-Xuan
Zhao, Zu-Jiang
Huang, Xu-Sheng
Luo, Rong-Hua
Yang, Liu-Meng
Zhang, Mi
Dong, Xing-Qi
Li, Ming-Hua
Feng, Xiao-Li
Zhou, Qing-Cui
Qu, Wang
Jiang, Shibo https://orcid.org/0000-0001-8283-7135
Ouyang, Songying https://orcid.org/0000-0002-1120-1524
Zheng, Yong-Tang https://orcid.org/0000-0001-5469-0324
-
Funding
Funding for this research was provided by:
National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (U1802284)
National Natural Science Foundation of China (82071847)
National Natural Science Foundation of China (81971548)
National Natural Science Foundation of China (82151218)
National Natural Science Foundation of China (92169112)
National Natural Science Foundation of China (82172287)
- License Information
-
More Information
Article History
Received: 27 July 2022
Accepted: 27 October 2022
First Online: 10 November 2022
Competing interests
: Y.T.Z., W.P., Y.L., W.Q.H., X.Y.H., R.H.L., and F.S. are listed as inventors on the Chinese patent of “A recombinant fusion protein derived from HR domains in S2 subunit of SARS-CoV-2 and its application (authorization No.: ZL202111167024.2)” related to this work. The other authors declare no competing interests.
